Abstract:Background: EZH2, well-known for its canonical methyltransferase activity in transcriptional repression in many cancers including glioblastoma (GBM), has an understudied non-canonical function critical for sustained tumor growth. Recent GBM consortial efforts reveal complex molecular heterogeneity for which therapeutic vulnerabilities correlated with subtype stratification remain relatively unexplored. Current enzymatic EZH2 inhibitors (EZH2inh) targeting its canonical SET domain show limited efficacy and lack durable response, suggesting that underlying differences in the non-canonical pathway may yield new knowledge. Here, we unveiled dual roles of the EZH2 CXC domain in therapeutically-distinct, reactive oxygen species (ROS)-stratified tumors. Methods: We analyzed differentially expressed genes between ROS classes by examining cis-regulatory elements as well as clustering of activities and pathways to identify EZH2 as the key mediator in ROS-stratified cohorts. Pull-down assays and CRISPR knockout of EZH2 domains were used to dissect the distinct functions of EZH2 in ROS-stratified GBM cells. The efficacy of NF-κB-inducing kinase inhibitor (NIKinh) and standard-of-care temozolomide was evaluated using orthotopic patient-derived GBM xenografts. Results: In ROS(+) tumors, CXC-mediated co-interaction with RelB drives constitutive activation of non-canonical NF-κB2 signaling, sustaining the ROS(+) chemoresistant phenotype. In contrast, in ROS(-) subtypes, PRC2 methyltransferase activity represses canonical NF-κB. Addressing the lack of EZH2inh targeting its non-methyltransferase roles, we utilized a brain-penetrant NIKinh that disrupts EZH2-RelB binding, consequently prolonging survival in orthotopic ROS(+)-implanted mice. Conclusion: Our findings highlight the functional dichotomy of the EZH2 CXC domain in governing ROS-stratified therapeutic resistance, thereby advocating for the development of therapeutic approaches targeting its non-canonical activities and underscoring the significance of patient stratification methodologies.

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

Polycomb-independent Activity of EZH2 in Castration Resistant Prostate Cancer

EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells is Polycomb-Independent

EZH2-mediated development of therapeutic resistance in cancer

A Non-Canonical EZH2 Function Sensitizes Solid Tumors to Genotoxic Stress

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer

Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution

ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.

Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity

Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer

A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation

Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells

Polycomb Group Proteins EZH2 and EED Directly Regulate Androgen Receptor in Advanced Prostate Cancer

Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells.

EZH1/2 as targets for cancer therapy

Integrative Analysis Reveals the Transcriptional Collaboration Between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression

EZH2: a novel target for cancer treatment

Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer

EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma